Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 548

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

First‐in‐class cardiolipin‐protective compound as a therapeutic agent to restore mitochondrial bioenergetics

Open access
Szeto, Hazel H·2014·British Journal of Pharmacology

Abstract

A decline in energy is common in aging, and the restoration of mitochondrial bioenergetics may offer a common approach for the treatment of numerous age‐associated diseases. Cardiolipin is a unique phospholipid that is exclusively expressed on the inner mitochondrial membrane where it plays an important structural role in cristae formation and the organization of the respiratory complexes into supercomplexes for optimal oxidative phosphorylation. The interaction between cardiolipin and cytochrome c determines whether cytochrome c acts as an electron carrier or peroxidase. Cardiolipin peroxidation and depletion have been reported in a variety of pathological conditions associated with energy deficiency, and cardiolipin has been identified as a target for drug development. This review focuses on the discovery and development of the first cardiolipin‐protective compound as a therapeutic agent. SS‐31 is a member of the S zeto‐S chiller (SS) peptides known to selectively target the inner mitochondrial membrane. SS‐31 binds selectively to cardiolipin via electrostatic and hydrophobic interactions. By interacting with cardiolipin, SS‐31 prevents cardiolipin from converting cytochrome c into a peroxidase while protecting its electron carrying function. As a result, SS‐31 protects the structure of mitochondrial cristae and promotes oxidative phosphorylation. SS‐31 represents a new class of compounds that can recharge the cellular powerhouse and restore bioenergetics. Extensive animal studies have shown that targeting such a fundamental mechanism can benefit highly complex diseases that share a common pathogenesis of bioenergetics failure. This review summarizes the mechanisms of action and therapeutic potential of SS‐31 and provides an update of its clinical development programme. Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12461

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 168 references

Cited by

See all 548

Metadata

Authors
Szeto, H. H.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2014-03-28
Volume
171
Issue
8
Pages
2029-2050
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1722845210
Cited by
548
References
168
FWCI
8.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First‐in‐class cardiolipin‐protective compound as a therapeutic agent to restore mitochondrial bioenergetics. https://app.cochat.ai/papers/10.1111/bph.12461
The paper
Szeto, H. H. (2014). First‐in‐class cardiolipin‐protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. https://doi.org/10.1111/bph.12461

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.